Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mi-Ran Yun

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.
Cancer Research|April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK InhibitorsMi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.
Genome Announcements|August 15, 2015
Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus KOR/KNIH/002_05_2015, Isolated in South KoreaYou-Jin Kim, Yong-Joon Cho, Dae-Won Kim, et al.
British Journal of Cancer|September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neckHye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationHan Na Kang, Jae Woo Choi, Hyo Sup Shim, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckHan Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.
Cancer Research|April 20, 2018
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK InhibitorsMi Ran Yun, Sun Min Lim, Seon-Kyu Kim, et al.
Genome Announcements|August 15, 2015
Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus KOR/KNIH/002_05_2015, Isolated in South KoreaYou-Jin Kim, Yong-Joon Cho, Dae-Won Kim, et al.
British Journal of Cancer|September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neckHye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationHan Na Kang, Jae Woo Choi, Hyo Sup Shim, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckHan Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 7